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Protease-activated receptors (PARs) are widely expressed in the central nervous
system (CNS). While a firm link between PAR1-activation and functional synaptic and
intrinsic neuronal properties exists, studies on the role of PAR1 in neural structural
plasticity are scarce. The physiological function of PAR1 in the brain remains not
well understood. We here sought to determine whether prolonged pharmacologic
PAR1-inhibition affects dendritic morphologies of hippocampal neurons. To address this
question we employed live-cell microscopy of mouse dentate granule cell dendrites in 3-
week old entorhino-hippocampal slice cultures prepared from Thy1-GFP mice. A subset
of cultures were treated with the PAR1-inhibitor SCH79797 (1 µM; up to 3 weeks). No
major effects of PAR1-inhibition on static and dynamic parameters of dentate granule
cell dendrites were detected under control conditions. Granule cells of PAR1-deficient
slice cultures showed unaltered dendritic morphologies, dendritic spine densities and
excitatory synaptic strength. Furthermore, we report that PAR1-inhibition does not
prevent dendritic retraction following partial deafferentation in vitro. Consistent with
this finding, no major changes in PAR1-mRNA levels were detected in the denervated
dentate gyrus (DG). We conclude that neural PAR1 is not involved in regulating the
steady-state dynamics or deafferentation-induced adaptive changes of cultured dentate
granule cell dendrites. These results indicate that drugs targeting neural PAR1-signals
may not affect the stability and structural integrity of neuronal networks in healthy brain
regions.
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INTRODUCTION
Protease activated receptors (PAR) are G-protein coupled receptors, which are activated
by proteolytic cleavage of their N-terminal extracellular domain (Gingrich and Traynelis,
2000; Traynelis and Trejo, 2007; Zhao et al., 2014). This modification uncovers a tethered
ligand, which activates intracellular Gaq/11, Gai/o, or Ga12/13 proteins (Coughlin, 2000;
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Macfarlane et al., 2001; Traynelis and Trejo, 2007). While
PAR2 represents a class of trypsin/tryptase-activated receptors,
PAR1, PAR3, and PAR4 are effectively activated by thrombin
(Gingrich and Traynelis, 2000). Among other PAR-activating
proteases are plasmin, activated factor X, activated protein C,
and matrix metalloproteinases (Mosnier et al., 2012; Austin
et al., 2013; Gleeson et al., 2014). In the vascular system
PARs mediate important biological functions, such as blood
coagulation, vascular integrity, and inflammation (Alberelli and
De Candia, 2014; Hollenberg et al., 2014). In the brain, PAR1
is detected in the cerebral cortex, hippocampus, amygdala,
basal ganglia, and striatum (Weinstein et al., 1995; Niclou
et al., 1998; Striggow et al., 2001; Junge et al., 2004; Han
et al., 2011). Inhibition of PAR1 has been comprehensively
studied for its neuroprotective effects in various models of brain
injury (Striggow et al., 2001; Junge et al., 2003; Guo et al.,
2004; Olson et al., 2004; Nicole et al., 2005; Hamill et al.,
2007; Isaev et al., 2015). Furthermore, recent studies revealed
that the activation of PAR1 increases neural excitability and
affects the ability of neurons to express synaptic plasticity (Ben
Shimon et al., 2015). Likewise, evidence has been provided that
PAR1-activation triggers neurite retraction (Jalink et al., 1994;
Pai and Cunningham, 2002).
These findings are of considerable interest in the context
of neurological diseases, which are accompanied by a break-
down of the blood brain barrier (Rosenberg, 2012; Obermeier
et al., 2013) and/or increased brain serine protease levels
(Zhao et al., 2006, 2007; Amantea et al., 2007). Since novel
oral anticoagulants have been developed that target PAR1
(Morrow et al., 2012; Scirica et al., 2012; Bhandari and
Mehta, 2014) or affect PAR1-signals indirectly by blocking
thrombin or factor Xa-activity (Verheugt and Granger,
2015), it has been proposed that these drugs may exert
their positive effects seen in patients also by preventing the
activation of neural PAR1 under pathological conditions
(e.g., Luo et al., 2007; Maggio et al., 2013a). Hence, it
has been speculated that neural PAR1-inhibitors may
prove suitable for the treatment of several neurological
diseases associated with alterations in blood-brain barrier
function and/or increased PAR1-activity (Boven et al.,
2003; Ishida et al., 2006; Rosenberg, 2012). However, the
role of PAR1 in normal brain function remains not well
understood.
We here employed 3-week old (≥18 days in vitro, DIV)
entorhino-hippocampal slice cultures prepared from Thy1-GFP
mice (Feng et al., 2000) to study the effects of prolonged
pharmacologic PAR1-inhibition on static and dynamic
properties of mature dentate granule cell dendrites. Live-
cell microscopy was used to follow the dynamics of dendritic
changes in identified GFP-expressing mature dentate granule
cells over a period of up to 3 weeks in vitro. In addition,
we tested whether PAR1 mediates dendritic retraction
in response to entorhinal cortex lesion in vitro (Müller
et al., 2010; Vlachos et al., 2012, 2013a), which is a strong
stimulus for neurons to remodel their dendrites (Steward,
1994; Deller and Frotscher, 1997; Perederiy and Westbrook,
2013).
MATERIALS AND METHODS
Ethics Statement
Mice were maintained in a 12 h light/dark cycle with food and
water available ad libitum. Every effort was made to minimize
distress of animals. All experimental procedures were performed
according to German animal welfare legislation and approved
by the animal welfare officer of Goethe-University Frankfurt,
Faculty of Medicine.
Preparation of Slice Cultures
Entorhino-hippocampal slice cultures were prepared at postnatal
day 4–5 from heterozygous Thy1-GFP mice (Feng et al., 2000)
and C57BL/6J mice of either sex as previously described (e.g.,
Vlachos et al., 2013b; Lenz et al., 2016). In some experiments
PAR1-deficient mice (PAR1-KO; B6.129S4-F2rtm1Ajc/J; from
Jackson Laboratories, USA) and their wild type littermates were
used (c.f., Becker et al., 2013). Each filter inset contained up to six
cultures prepared from one animal. Cultures from at least three
independent litters were used in the experiments. Cultivation
medium contained 50% (v/v) MEM, 25% (v/v) basal medium
eagle, 25% (v/v) heat-inactivated normal horse serum, 25 mM
HEPES buffer solution, 0.15% (w/v) bicarbonate, 0.65% (w/v)
glucose, 0.1 mg/ml streptomycin, 100 U/ml penicillin, and 2 mM
glutamax. The pH was adjusted to 7.3 and the medium was
replaced three times per week. All slice cultures were allowed to
mature for at least 18 days in humidified atmosphere with 5%
CO2 at 35◦C.
Pharmacology
SCH79797 [IC50 = 70 nM; Tocris Bioscience, UK] was used
to block PAR1. Tetrodotoxin (TTX) and D(-)-2-amino-5-
phosphonovaleric acid (D-AP5; both from Tocris Bioscience,
UK) were used for electrophysiological recordings. Handling and
disposal of all drugs carried out in accordance to German and
University regulations.
Entorhinal Cortex Lesion
Slice cultures (18–20DIV) were transected from the rhinal fissure
to the hippocampal fissure using a sterile scalpel blade. The
entorhinal cortex was removed from the culturing dish in every
denervation experiment.
Long-Term Time-Lapse Imaging of Slice
Cultures
Live imaging of slice cultures was performed as described
previously (e.g., Vlachos et al., 2012, 2013a). The imaging buffer
contained 129 mMNaCl, 4 mMKCl, 1 mMMgCl2, 2 mMCaCl2,
4.2 mM glucose, 10 mM HEPES, 0.1 mM Trolox, 0.1 mg/ml
streptomycin, 100 U/ml penicillin (pH 7.4; 35◦C; osmolarity was
adjusted with sucrose to match the osmolarity of the cultivation
medium). Cultures (starting at 18–20 DIV) were viewed with
an upright Zeiss LSM Pascal confocal microscope. A 10× water
immersion objective (0.3 NA, Zeiss, Germany) was used to
visualize the culture at low magnification to identify individual
granule cells. Then a 40× water immersion objective (0.9 NA;
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Zeiss, Germany) was used to image the dendritic tree of a
single granule cell. Up to 40 images were recorded per stack
(512 × 512 pixel, 0.45 µm/pixel; z-steps: 3 µm). Per filter insert
(containing up to six cultures, prepared from one animal) one
identified granule cell was visualized to minimize dwell time
during imaging procedure (<10 min per culture). The dendritic
trees of individual GFP-expressing granule cells were repeatedly
imaged for up to 3 weeks using the same imaging procedure and
settings at the microscope.
Reconstruction of the Dendritic Tree
The dendritic tree of individual imaged dentate granule cells
was manually reconstructed in confocal image stacks using
SpineLab 0.4 (Jungblut et al., 2012). In some cases single dendritic
segments were excluded from the analysis because they were
not completely mapped on single or several points of time. As
reported previously the validity of reconstructions was confirmed
by reconstructing a subset of neurons with Neurolucida Software
10.0 [MBF Bioscience; c.f., (Jungblut et al., 2012)]. Sholl analysis
was performed on Neurolucida-reconstructed PAR1-deficient
granule cells using the NeuroExplorer software (Neurolucida
Software 10.0; MBF Bioscience) as described previously (Vuksic
et al., 2011; Hick et al., 2015). In short, a series of concentric
spheres were centered on the soma and mapped onto the 3D-
reconstruction with increasing radius (40 µm increments). The
number of reconstructed dendrites crossing each sphere was
determined.
Laser Capture Microdissection
Slice cultures were washed with phosphate buffered saline (PBS;
0.1 M, pH 7.4), shock frozen at −80◦C in tissue freezing
medium (Leica Microsystems, Germany), re-sliced into 10 µm
thick slices on a cryostat (Leica CM 3050 S) and mounted on
PET foil metal frames (Leica, Germany) as described previously
(Becker et al., 2013, 2015). Re-sliced cultures were fixed in
ice-cold acetone for 1 min and incubated with 0.1% (v/v)
toluidine blue (Merck, Germany) at room temperature for 1 min
to visualize cytoarchitecture, before rinsing in ultrapure water
(DNase/RNase free, Invitrogen, USA) and 70% (v/v) ethanol.
PET foil metal frames were mounted on a Leica DM 6000B laser
capture microdissection (LMD) system (Leica Microsystems,
Germany) with the section facing downward (Burbach et al.,
2003). After adjusting intensity, aperture, and cutting velocity,
the pulsed ultraviolet laser beam was carefully directed along
the borders of the respective layers of the dentate gyrus
(DG) using a 20× objective lens (Leica Laser Microdissection,
Software Version 7.4.1.4853). Tissue was collected from the
outer molecular layer (OML), the inner molecular layer (IML)
and the granule cell layer (GCL) of the DG. Microdissected
tissue was transferred by gravity into microcentrifuge tube caps
placed underneath the sections, filled with 50 µl guanidine
isothiocyanate (GITC)-containing buffer (RLT Buffer, RNeasy
Mini Kit, Qiagen, Germany) with 1% (v/v) β-mercaptoethanol
(AppliChem GmbH, Germany). Successful tissue collection was
verified by visually inspecting the content of the tube caps. All
samples were frozen and stored at−80◦C.
Isolating RNA and qPCR
RNA was isolated using the RNeasyr MicroPlus Kit (Qiagen,
Germany). Purified RNA was transcribed into cDNA with
the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, MA, USA). All kits and assays were used according
to the manufacturer’s instructions. The cDNA was amplified
using the TaqManr PreAmp Master Mix Kit (Applied
Biosystems, MA, USA) using 5 µl PreAmp Master Mix (Applied
Biosystems, MA, USA) + 2.5 µl cDNA + 2.5 µl Assay
Mix [TaqMan Gene ExpressionTM-Assay; GAPDH: 4352932E;
PAR1: MM00438851_m1 from Applied Biosystems, MA, USA]
with a standard amplification protocol (14 cycles: 95◦C for 15 s,
60◦C for 4 min). Amplified cDNAs were diluted 1:20 in ultrapure
water and subjected to qPCR (StepOnePlus, Applied Biosystems,
USA) using a standard amplification program (1 cycle of 50◦C
for 2 min, 1 cycle of 95◦C for 10 min, 40 cycles of 95◦C for 15 s
and 60◦C for 60 s cut off at 30 cycles; average CT-value PAR1:
26.5± 0.2 cycles).
Whole-Cell Patch-Clamp Recordings
Whole-cell voltage-clamp recordings of miniature excitatory
postsynaptic currents (mEPSCs; at 35◦C) and post hoc
identification of recorded neurons were carried out in slice
cultures prepared from PAR1-deficient mice as previously
described (e.g., Vlachos et al., 2013a). Briefly, mEPSCs were
recorded in artificial cerebrospinal fluid (ACSF: 126 mM
NaCl, 2.5 mM KCl, 26 mM NaHCO3, 1.25 mM NaH2PO4,
2 mM CaCl2, 2 mM MgCl2, and 10 mM glucose) in 10
µM D-AP5 and 0.5 µM TTX saturated with 95% O2/5%
CO2. Patch pipettes contained 126 mM K-gluconate, 4 mM
KCl, 4 mM ATP-Mg, 0.3 mM GTP-Na2, 10 mM PO-
Creatine, 10 mM HEPES and 0.3% Biocytin (pH = 7.25
with KOH, 290 mOsm with sucrose). Dentate granule cells
were recorded at a holding potential of −70 mV. Series
resistance was monitored in 2 min intervals, and recordings
were discarded if the series resistance and leak current
changed significantly and/or reached ≥30 MΩ or ≥50 pA,
respectively.
Slice Culture Fixation, Staining and
Imaging
Slice cultures were fixed in a solution of 4% (w/v)
paraformaldehyde (PFA) in phosphate buffered saline (PBS,
0.1 M, pH 7.4) and 4% (w/v) sucrose for 1 h, followed by 2%
PFA and 30% sucrose in PBS overnight. Fixed slice cultures
were thoroughly washed and stained with Alexa568 coupled
streptavidin (1:500) in PBS with 10% (v/v) normal horse serum
and 0.1% (v/v) Triton X-100 for 2 h. Sections were washed
again, transferred onto glass slides and mounted for visualization
with anti-fading mounting medium. Confocal image stacks
of dentate granule cells were acquired using a Nikon Eclipse
C1si laser-scanning microscope with a 40× objective lens (NA
1.3, Nikon Instruments, Germany). In addition individual
dendritic segments in the OML were imaged at 4× scan
zoom using a 60× objective lens (NA 1.4, oil immersion,
Nikon Instruments, Germany). Detector gain and amplifier
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were initially set to obtain pixel intensities within a linear
range.
Quantification and Statistics
Dendritic morphologies of cultured dentate granule cells
treated with SCH79797 [1 µM] were compared to age-
and time-matched granule cells of untreated, i.e., vehicle-
treated cultures, which were imaged the same number
of times using the same imaging protocol. In addition,
age- and time-matched denervated dentate granule cells
that were vehicle- or SCH79797-treated were assessed. 3D
reconstructions were performed with the person analyzing
dendritic morphologies blind to experimental condition. The
dynamics of dendrites were assessed by determining changes
in dendritic length of individual branches at consecutive points
in time. The sum of elongation events and retraction events
between two imaging sessions was normalized to the total
reconstructed dendritic length at the respective point in time.
The dendritic remodeling index was defined as mean elongation
+ mean retraction amount, divided by mean total dendritic
length (TDL).
Dendritic spine numbers of Alexa568-streptavidin stained
granule cells in PAR1-deficient preparations and their age-
and time-matched wild type littermates were assessed using
NeuroExplorer software (Neurolucida Software 10.0; MBF
Bioscience; c.f., Hick et al., 2015). At least 60 µm of dendritic
length from three different dendritic segments per neuron were
analyzed in the OML of the dentate gyrus by an investigator blind
to genotype.
qPCR-data were analyzed as described by Pfaffl (2001).
GAPDH served as reference gene in this analysis. The qPCR
assay efficiency was calculated with the StepOnePlus software
(Applied Biosystems, MA, USA) based on a dilution series of
five samples (whole hippocampi) for each assay. Since PAR1-
mRNA levels were not significantly different in non-denervated
controls at 18–20 DIV and 32 DIV these data were pooled and
used for statistical comparisons (Kruskal-Wallis-test followed
by Dunn’s post hoc-test, which takes multiple comparisons into
account).
Electrophysiological data were analyzed using pClamp 10.2
(Axon Instruments, CA, USA) and MiniAnalysis (Synaptosoft,
GA, USA) software. All events were visually inspected and
detected by an investigator blind to experimental condition;
200–300 events were analyzed per recorded neuron.
Sample sizes were chosen according to initial
pilot experiments and prior studies that used similar
experimental approaches to detect changes in dendritic
morphologies/dynamics, spine densities, mEPSC properties
and mRNA levels (e.g., Vlachos et al., 2009; Becker et al., 2013;
Willems et al., 2016). Data were analyzed using GraphPad Prism
6 (GraphPad Software). Statistical comparisons were made using
non-parametric Mann-Whitney-test or the Kruskal-Wallis-test
followed by Dunn’s post hoc-test.
P-values of less than 0.05 were considered significant. All
values represent means ± standard error of the mean (sem). In
the figures not significant differences are indicated with ‘‘NS’’.
Digital Illustrations
Confocal image stacks were exported as 2D-projections
from the Zeiss LSM image browser and stored as TIF
files. Figures were prepared using Photoshop graphics
software (Adobe, CA, USA). Contrast and brightness
was adjusted based on the reconstruction skeletons to
improve visualization of reconstructed neurons in the
2D-projections.
RESULTS
Pharmacologic Inhibition of PAR1 does not
Affect Basic Morphological Parameters of
Dentate Granule Cell Dendrites
Dendritic trees of identified GFP-expressing granule cells were
imaged in 6-week old entorhino-hippocampal slice cultures
and reconstructed in 3D-image stacks (Figures 1A,B). TDL
was determined in untreated control cultures and cultures
that were treated for 3 weeks with SCH79797 (1 µM;
treatment started 18–21 days after preparation), a potent
and highly specific inhibitor of PAR1 (Ahn et al., 2000).
No significant difference was detected between untreated
and SCH79797-treated granule cells in these experiments
(Figure 1C). We also compared the mean number of
dendrites per dendritic branch order and did not find a
significant difference between the two groups (Figure 1D).
These initial results indicated that prolonged, i.e., 3-weeks
of PAR1-inhibition does not cause major changes in TDL
or dendritic branching of mature cultured mouse dentate
granule cells.
Time-Lapse Imaging Reveals the
Dynamics of Granule Cell Dendrites in
Untreated and SCH79797-Treated Slice
Cultures
Since the morphological parameters described above do not
exclude the possibility that dynamic properties of dendrites are
affected by pharmacologic PAR1-inhibition, we next employed
live-cell microscopy to assess dendritic changes over time
(Figure 2). Identified dentate granule cells were imaged
repeatedly at selected points in time over a period of 3 weeks
(between 3 and 6 weeks in vitro; Figure 2A) and their dendritic
trees were reconstructed (Figure 2B). A set of cultures was
treated with 1 µM SCH79797 (treatment started immediately
after the first imaging session at 18–21 DIV). As shown in
Figure 2C no significant difference in TDL was observed
between the two groups. A slight trend towards reduced TDL
was detected in these experiments, which, however, did not
reach the level of significance in both groups (Kruskal-Wallis-
test following Dunn’s post hoc-test; p = 0.17). We conclude
from these experiments that TDL of dentate granule cells
remains constant (between 3 and 6 weeks in vitro) in untreated
control cultures and that pharmacologic inhibition of PAR1
has no major impact on TDL in our experimental setting (c.f.,
Figure 1).
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FIGURE 1 | Dendritic morphologies of cultured mouse dentate granule cells are not affected by pharmacologic protease-activated receptor
(PAR)-inhibition under control conditions. (A) Organotypic entorhino-hippocampal slice culture stained for TO-PROr nuclear stain. EC, entorhinal cortex; DG,
dentate gyrus. Scale bar = 300 µm. (B) Individual GFP-expressing dentate granule cells are imaged in the suprapyramidal blade of the DG of 6-week-old
entorhino-hippocampal slice cultures. Dendritic morphologies are reconstructed in 3D-image stacks. Scale bar = 30 µm. (C) Pharmacological inhibition of PAR1 for
3 weeks in vitro with SCH79797 [1 µM] does not affect total dendritic branch length (TDL) of cultured dentate granule cells. Untreated, n = 7 neurons; SCH79797,
n = 5 neurons. Mann-Whitney-test (NS, not significant). (D) The mean number of dendritic segments per branch-order is not significantly different between the two
groups. Kruskal-Wallis-test following Dunn’s post hoc-test (NS, not significant).
We then quantified dendritic elongation and retraction
between consecutive points in time in untreated and
SCH79797-treated control cultures (Figure 2D). Dendritic
changes were predominantly (but not exclusively) observed
in distal portions of the dendritic tree (c.f., asterisk in
Figure 2B). This analysis disclosed that mature, i.e.,
≥18 DIV old granule cell dendrites are in a dynamic
steady-state, in which elongation and retraction are in a
homeostatic equilibrium. PAR1-inhibition did not affect
the steady-state dynamics of cultured mouse granule cell
dendrites. While TDL remained constant, the dendritic
turnover index (sum of mean elongation and mean
retraction amount, divided by mean TDL), was not
significantly different between the two groups (Figure 2E).
In both SCH79797-treated and untreated slice cultures
approximately 5% of TDL (i.e., 64 ± 2 µm) was remodeled
between consecutive points in time. We did not observe
any dendritic segments to be completely lost or new
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FIGURE 2 | PAR1-inhibition does not affect dendritic dynamics of cultured mouse dentate granule cells under control conditions. (A) Schematic of the
experimental design. Slice cultures prepared at postnatal day 4–5 are allowed to mature for 18–20 days in vitro (DIV). Repeated live-cell microscopy is performed at
indicated points in time. A subset of cultures are treated with SCH79797 [1 µM] immediately after the first imaging session for the entire observation period. (B)
SCH79797-treated dentate granule cell. Dynamic changes are predominantly (but not exclusively; see asterisk) observed at distal tips of dendrites. Arrow points at
example of dendritic elongation, arrowhead at dendritic retraction, circle indicates a stable dendritic segment. Scale bar = 30 µm. (C) TDL of untreated and
SCH79797-treated dentate granule cells at indicated points in time. Values normalized to TDL of the first imaging session, respectively. n = 5 neurons each.
Kruskal-Wallis-test following Dunn’s post hoc-test (NS, not significant). (D) Elongation and retraction rates are comparable in the two groups. Kruskal-Wallis-test
following Dunn’s post hoc-test (NS, not significant). (E) Accordingly, the dendritic remodeling index, i.e., sum of mean elongation and retraction amounts, divided by
mean TDL, is not significantly different between the two groups. Approximately 5% of TDL (corresponding to an average of 64 ± 2 µm) is dynamically changed
between consecutive imaging sessions. Mann-Whitney-test (NS, not significant).
segments to be formed during the observation period in
both groups.
SCH79797 does not Prevent
Denervation-Induced Dendritic Retraction
To further assess the role of PAR1 in dendritic plasticity, we
employed entorhinal denervation in vitro (Figure 3). Previous
work has shown that the maintenance of granule cell dendrites
requires entorhinal input (Caceres and Steward, 1983; Diekmann
et al., 1996; Müller et al., 2010; Nitsch and Frotscher, 1993).
Hence, in a different set of 3-week-old slice cultures the
entorhino-hippocampal projection was transected to test for
the effects of PAR1-inhibition on denervation-induced dendritic
retraction (Figure 3A). The entorhinal cortex was removed from
the culturing dish after the first imaging session and a subset
of cultures were treated with SCH79797 [1 µM] immediately
after the lesion for 14 days until the second imaging session
(Figure 3A). The lesion does not damage the DG directly (Müller
et al., 2010), but leads to the partial loss of innervating axons
on distal portions of dentate granule cell dendrites. Identified
GFP-expressing granule cells were imaged again 14 days later
(Figures 3A,B). Indeed, a reduction in TDL was observed
14 days post lesion in untreated denervated cultures (Figure 3C).
However, a similar effect of denervation on TDL was seen in the
SCH79797-treated group (Figure 3C). Thus, PAR1-inhibition
does not prevent the denervation-induced net reduction in TDL.
We then determined elongation and retraction rates and also
calculated the dendritic remodeling index in denervated slice
cultures (Figures 3D,E). No significant difference was detected
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FIGURE 3 | Denervation-induced net retraction of cultured mouse dentate granule cell dendrites is not affected by PAR1-inhibition. (A) Experimental
design and schematic illustration of an organotypic entorhino-hippocampal slice culture (top). The entorhino-hippocampal fiber tract (green) terminating on distal
portions of granule cell dendrites in the DG and the plane of transection (red) are illustrated (EC, entorhinal cortex). TO-PROr nuclear stain of a denervated slice
culture. In all denervation experiments the EC is removed after the first imaging session and prior to pharmacological treatment using a sterile scalpel. Identified
GFP-expressing dentate granule cells are imaged again 14 days later. Scale bar = 300 µm. (B) 2D-projected image stacks and corresponding reconstructions of
Thy1-GFP expressing dentate granule cells imaged at 0 and 14 days post lesion (dpl). For comparison a non-denervated granule cell treated with the PAR1-inhibitor
SCH79797 [1 µM] is illustrated at 0 and 14 days (c.f., Figure 2). Arrow points at example of dendritic elongation, arrowhead at dendritic retraction. Dendritic
retraction is predominantly (but not exclusively; see asterisk) observed in distal portions of the dendritic tree. Scale bar = 30 µm. (C) Mean net loss of TDL in
response to EC lesion in vitro is given for untreated and SCH79797-treated denervated dentate granule cells. n = 6 neurons in each group. Mann-Whitney-test (NS,
not significant). (D) Elongation and retraction rates are not significantly different between the two groups. Mann-Whitney-test (NS, not significant). (E) The dendritic
remodeling index, i.e., sum of elongation and retraction amounts divided by TDL, is not significantly different between the two groups. Approximately 25% of TDL
(corresponding to 219 ± 30 µm) is remodeled between 0 and 14 dpl. This calculation underestimates the dynamics of granule cell dendrites, since elongation and
retraction events occurring between the two imaging time-points escape detection. Mann-Whitney-test (NS, not significant).
between the two groups in this analysis. Denervation caused
an increase in dendritic dynamics, with ∼25% of TDL being
remodeled between 0 and 14 days post lesion (Figure 3E). PAR1-
inhibition had no apparent effect on the dynamic reorganization
of dendrites: elongation and retraction of dendrites was similar
in untreated and SCH79797-treated denervated cultures. We
conclude that pharmacologic PAR1-inhibition does not affect
denervation-induced dendritic adaptations of cultured dentate
granule cells.
No Major Changes in PAR1-mRNA Levels
in the Denervated Dentate Gyrus
To test whether the loss of input triggers changes in
PAR1-expression in the denervated zone, LMD combined
with qPCR analysis was employed (Figure 4). Tissue
isolated from the GCL, the IML and the denervated OML
at 1, 2, 4, 7 and 14 dpl was subjected to qPCR analysis
(Figure 4A). While PAR1-mRNA was robustly detected
in all layers of the DG in our preparations, no significant
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FIGURE 4 | No major changes in PAR1-mRNA levels are detected in the denervated DG of mouse entorhino-hippocampal slice cultures. (A) Tissue
from the granule cell layer (GCL; black), the inner molecular layer (IML; blue) and the denervated outer molecular layer (OML; red) was isolated by laser
microdissection from denervated cultures at 1, 2, 4, 7, and 14 dpl and from non-denervated control cultures (CTL). Scale bar = 50 µm. (B) Isolated tissue was
subjected to qPCR analysis. Values are normalized to non-denervated controls. No significant changes in PAR1-mRNA levels were observed in the denervated DG in
response to EC lesion in vitro. n = 3–11 cultures per group. Kruskal-Wallis-test followed by Dunn’s post hoc-test (NS, not significant).
changes in PAR1-mRNA levels were observed following
entorhinal denervation in vitro (Figure 4B; a slight, but
not significant increase was seen in the GCL during the
early phase after denervation; Kruskal-Wallis-test following
Dunn’s post hoc-test; p = 0.46). The results of these
experiments disclosed that the loss of axonal input does
not trigger major changes in PAR1-expression in the
denervated DG of hippocampal slice cultures (c.f., Becker
et al., 2013, 2015; on increased mRNA-levels of tumor
necrosis factor and its receptors after denervation; Willems
et al., 2016 on increased sphingosine-phosphate-receptor
mRNA).
Dentate Granule Cells of PAR1-Deficient
Slice Cultures Show No Major Alterations
in Dendritic Morphologies, Dendritic Spine
Densities and Excitatory Synaptic Strength
Finally, slice cultures prepared from PAR1-deficient mice
and their age- and time-matched wild type littermates
were used to compare dendritic morphologies of dentate
granule cells. Individual dentate granule cells were patched
and filled with biocytin followed by Alexa568-Streptavidin
staining (Figure 5A). As shown in Figures 5B–D, we did
not observe any significant difference in TDL, the number
of branches per order and number of Sholl intersections
between the two groups. Interestingly, a trend towards
higher TDL was observed in granule cells of both PAR1-
deficient and wild type littermate cultures as compared
to Thy1-GFP mice (c.f., Figure 1), which have a different
genetic background. Although this difference did not reach
the level of significance (Kruskal-Wallis-test following
Dunn’s post hoc-test; p = 0.1), the observation underscores
the importance of using wild type littermates when
assessing dendritic morphologies of transgenic animals.
We also assessed dendritic spine densities in the OML
of PAR1-deficient and wild type cultures and did not
find a significant difference between the two genotypes
(Figure 5E). Consistent with these findings mEPSCs were
unaltered in granule cells of PAR1-deficient preparations as
compared to their age- and time-matched wild type littermates
(Figures 5F,G; c.f., Becker et al., 2014). Altogether, these
results supported our pharmacological experiments using 1 µM
SCH79797, and, furthermore, suggested that PAR1-deficiency
does not affect dendritic maturation of cultured dentate
granule cells.
DISCUSSION
The present study addresses the effects of prolonged
pharmacologic PAR1-inhibition in dendritic plasticity under
control, i.e., steady-state conditions and following in vitro
deafferentation. Our experiments disclose dynamics of
dentate granule cell dendrites. Using live-cell microscopy
of entorhino-hippocampal slice cultures prepared from
Thy1-GFP mice we were able to demonstrate that granule
cell dendrites are in a homeostatic, i.e., ‘‘stable dynamic
state’’: while TDL and dendritic branching remains constant,
spontaneous dendritic remodeling is detected. This dendritic
homeostasis is challenged by entorhinal denervation in vitro.
As a consequence dendritic remodeling increases substantially,
leading to a net reduction in TDL (see also Willems et al.,
2016). Denervated neurons may eventually reach a new
stable dynamic state at a later time point after the lesion
(Caceres and Steward, 1983; Vuksic et al., 2011). PAR1-
inhibition has no major effect on dendritic dynamics, both
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FIGURE 5 | Dendritic morphologies, spine density and excitatory synaptic currents of dentate granule cells prepared from PAR1-deficient mice.
(A) Examples of Alexa568-stained biocytin filled granule cells in slice cultures prepared from PAR1-deficient mice and wild type littermates. Dendritic morphologies
were reconstructed in 3D-image stacks. Scale bar = 30 µm. (B–D) TDL (B), the mean numbers of dendritic segments per branch-order (B) and Scholl-analysis (C)
are not significantly different between the two groups. (n = 4 wild type neurons; n = 5 PAR1-deficient neurons; from three cultures each; Mann-Whitney-test in B;
Kruskal-Wallis-test following Dunn’s post hoc-test in C; NS, not significant). (E–G) Dendritic spine densities in the outer molecular layer (OML) are comparable
between the two groups (n = 6 neurons each group). Consistent with this finding no significant difference in miniature excitatory postsynaptic currents (mEPSCs)
recorded from PAR1-deficient and wild type dentate granule is detected. (n = 7 wild type neurons; n = 8 PAR1-deficient neurons; from four cultures each;
Mann-Whitney-test; NS, not significant).
under control conditions and following partial denervation in
vitro. Hence, our experiments suggest that PAR1 is not involved
in maintaining TDL or dendritic branching under control
conditions, nor is it linked to spontaneous or lesion-induced
dendritic elongation and retraction events; a suggestion that
is also supported by our LMD-qPCR results on unaltered
PAR1-mRNA levels in the denervated DG. Consistent with
these findings we did not observe any significant difference
in dendritic morphologies (and spine densities) between
dentate granule cells of PAR1-deficient and wild type littermate
cultures. Although more subtle structural and functional
alterations of dentate granule cells may have escaped our
detection (e.g., Krueppel et al., 2011; Kamijo et al., 2014),
these results suggest that PAR1 is not a major component of
the homeostatic machinery that maintains dendrites under
control conditions. PAR1 is not required to mediate the
adjustment of dendritic morphologies in denervated brain
regions.
The Physiological Function of Neural PAR1
Remains Not Well Understood
Despite numerous studies, which have addressed the
effects of PAR1-activation on neural excitability, synaptic
plasticity and in the context of neuroprotection, the role
of PAR1 for physiological brain functions remains not
well understood. The majority of studies conducted in
this field of research are based on experiments that employ
pharmacologic activation of PAR1 or PAR1-inhibition under
pathological conditions. It has been shown for example that
PAR1-activation (with high concentration of thrombin or
SFLLRN, a specific activating peptide) persistently increases
neuronal sodium currents (Isaeva et al., 2012), modulates
inhibitory synaptic transmission (Hashimotodani et al.,
2011; Maggio et al., 2013b) and enhances NMDA-R activity
(Gingrich et al., 2000; Lee et al., 2007; Maggio et al., 2008;
Han et al., 2011; Becker et al., 2014; Vance et al., 2015).
Furthermore, evidence has been provided that the activation
of PAR1 occludes the ability of neurons to express synaptic
plasticity under certain pathological conditions (Becker
et al., 2014; Stein et al., 2015). While these results are
relevant in diseases associated with increased neural PAR1-
activity, they do not address the relevance of PAR1-signals
in physiological brain function. In fact, the endogenous
activators of PAR1 in the central nervous system (CNS)
remain unknown (Kuliopulos et al., 1999; Nagai et al.,
2006).
The physiological role of PAR1 in synaptic plasticity and
memory formation has been recently addressed in a study
using PAR1-deficient mice (Almonte et al., 2013). Indeed,
alteration in Hebbian plasticity at Schaffer collateral-CA1
synapses and behavioral deficits in contextual fear conditioning
were reported. These results are in favor of a role of neural
PAR1 in learning and memory formation under physiological
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conditions. As discussed by Almonte et al. (2013), however,
known limitations of models of constitutive gene deficiency
cannot be ruled out. For example, developmental disturbances or
compensatory mechanisms may have influenced the ability
of neurons to express plasticity, rather than the lack of
PAR1 per se. Notably, studies employing pharmacologic
inhibition of PAR1 do not show major alterations in neuronal
synaptic plasticity (Becker et al., 2014; Stein et al., 2015).
Furthermore, PAR1-inhibition with SCH79797 [1 µM] has
been shown to rescue the ability of neurons to express LTP at
Schaffer-collateral CA1 synapses under conditions of increased
PAR1-activity (Stein et al., 2015). The experiments of the
present study reveal that 1 µM SCH79797 has no major
effects on dendritic morphologies of cultured dentate granule
cells. Furthermore, no alterations in dendritic morphologies,
dendritic spine counts and excitatory synaptic strength are
observed in granule cells of PAR1-deficient slice cultures.
Apparently, more work is required to unravel the role of
neural PAR1-activation under physiological conditions, and
the precise molecular mechanisms of PAR1-mediated neural
plasticity.
PAR1 is Not Involved in Mediating
Denervation-Induced Plasticity
Since no apparent effect of PAR1-inhibition on dendritic
dynamics under control conditions was detected, we
wondered whether PAR1 is involved in mediating dendritic
retraction following deafferentation. This appeared to be a
possibility, since earlier work demonstrated that thrombin-
mediated PAR1-activation induces neurite retraction in
neuroblastoma derived cell lines (Jalink et al., 1994; Pai and
Cunningham, 2002). Accordingly, we employed in vitro
entorhinal cortex lesion and expected that SCH79797 will
prevent the denervation-induced dendritic retraction: we
found a normal retraction response in these experiments.
Both the net reduction in TDL and the increase in dendritic
dynamics were not affected by the PAR1-inhibitor. In
line with this observation, we did not observe major
changes in PAR1-mRNA levels after denervation. These
findings argue against a role of neural PAR1-activity in
dendritic plasticity under control conditions and following
deafferentation.
The results are in line with our previous work on the
role of PAR1-inhibition in denervation-induced homeostatic
synaptic plasticity (Becker et al., 2014). In this earlier study
we were able to show that pharmacologic inhibition of
PAR1 does not prevent the compensatory, i.e., homeostatic
strengthening of granule cell excitatory synapses in response
to entorhinal cortex lesion in vitro (Becker et al., 2014).
Similarly, baseline synaptic transmission and denervation-
induced homeostatic synaptic strengthening is not affected
in granule cells of PAR1-deficient preparations (Becker
et al., 2014). The results of the present study confirm and
extend previous findings, since no significant difference
in mEPSC amplitudes and frequencies was observed and
spine densities were comparable in PAR1-deficient slice
cultures and wild type littermates. Taken together, we
propose that PAR1-inhibition has no major impact on
the ability of neurons to adjust structural and functional
properties of neurons in response to perturbations of network
activity.
Clinical Implications
Neurological diseases are often accompanied by neuronal
cell death and widespread secondary changes in connected
brain regions, which are mainly caused by the loss of
innervating axons originating from neurons at the primary
lesion site. This situation severely disrupts otherwise unaffected
and healthy brain areas and perturbs network function
(Steward, 1994; Deller and Frotscher, 1997; Perederiy and
Westbrook, 2013; Sharp et al., 2014). Our results suggest
that pharmacologic PAR1-inhibtion will not affect neural
homeostasis, i.e., structural and functional adaptations occurring
in denervated but otherwise healthy brain regions. It is
tempting to speculate that PAR1-inhibition may protect
neuronal networks from alterations in plasticity and could even
restore the ability of neurons to adjust structure and function
in a homeostatic manner under conditions of pathological
PAR1-activation. Indeed, our previous work disclosed that
PAR1-activation occludes the ability of neurons to express
homeostatic synaptic plasticity (Becker et al., 2014). Hence,
neural PAR1-inhibitors may exert beneficial effects: (1) by
the well documented neuroprotective effects at primary lesion
sites, e.g., by preventing neural cell death and apoptosis; (2)
by restoring the ability of neurons to express plasticity in
adjacent brain regions exhibiting increased PAR1-activity; and
(3) by not affecting compensatory structural and functional
adaptations in remote denervated and non-denervated brain
regions, which are not directly affected by the primary
lesion site.
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